Metraipolis › archive › dc_e5b224243f68
Lipid and Cholesterol Homeostasis after Arsenic Exposure and Antibiotic Treatment in Mice: Potential Role of the Microbiota — Europe PMC PMID:31532247
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/31532247
- DOI
- 10.1289/ehp4415
- License (as archived)
- CC0-1.0
- Archived
- 2026-11-10T13:51:04.965Z
- SHA-256 of the archived text
f4ec66e35a5f1daca754206b3cf8f4b47b679e3e426e1e6cfb9a12340a73aefe- Stable URL of this page
https://metraipolis.com/documento/dc_e5b224243f68
How to cite
Lipid and Cholesterol Homeostasis after Arsenic Exposure and Antibiotic Treatment in Mice: Potential Role of the Microbiota — Europe PMC PMID:31532247 — Europe PMC (en), https://europepmc.org/article/MED/31532247 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_e5b224243f68 (Metraipolis archive dc_e5b224243f68, sha256 f4ec66e35a5f1daca754206b3cf8f4b47b679e3e426e1e6cfb9a12340a73aefe)
BibTeX
@misc{dce5b224243f68,
title = {Lipid and Cholesterol Homeostasis after Arsenic Exposure and Antibiotic Treatment in Mice: Potential Role of the Microbiota — Europe PMC PMID:31532247},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/31532247},
note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_e5b224243f68; sha256 f4ec66e35a5f1daca754206b3cf8f4b47b679e3e426e1e6cfb9a12340a73aefe},
year = {2026}
}Archived text
Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/31532247. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
Background: Arsenic-induced liver X receptor/retinoid X receptor (LXR/RXR) signaling inhibition is a potential mechanism underlying the cardiovascular effects caused by arsenic. The gut microbiota can influence arsenic toxic effects. Objective: We aimed to explore whether gut microbiota play a role in arsenic-induced LXR/RXR signaling inhibition and the subsequent lipid and cholesterol dysbiosis. Methods: Conventional and antibiotic-treated mice (AB-treated mice) were exposed to 0.25 ppm and 1 ppm arsenic for 2 wk. Hepatic mRNAs were extracted and sequenced. The expression levels of genes associated with LXR/RXR signaling were quantified by quantitative real-time polymerase chain reaction (qPCR), and serum and hepatic cholesterol levels were measured. Liquid chromatography-mass spectrometry (LC-MS)-based lipidomics were used to examine serum and hepatic lipids. Results: Pathway analysis indicated that arsenic exposure differentially influenced the hepatic signaling pathways in conventional and AB-treated mice. The expression of sterol regulatory element-binding protein 1 ( Srebp1c ), 3-hydroxy-3-methylglutaryl-CoA reductase ( Hmgcr ), and cytochrome P450 family 7 subfamily A member 1 ( Cyp7a1 ), as well as cholesterol efflux genes, including ATP binding cassette subfamily G member 5/8 ( Abcg5/8 ) and cluster of differentiation 36 ( Cd36 ), was lower in arsenic-exposed conventional mice but not in AB-treated mice. Similarly, under arsenic exposure, the hepatic expression of scavenger receptor class B member 1 ( Scarb1 ), which is involved in reverse cholesterol transport (RCT), was lower in conventional mice, but was higher in AB-treated animals compared with controls. Correspondingly, arsenic exposure exerted opposite effects on the serum cholesterol levels in conventional and AB-treated mice, i.e., higher serum cholesterol levels in conventional mice but lower levels in AB-treated mice than in respective controls. Serum lipid levels, especially triglyceride (TG) levels, were higher in conventional mice exposed to 1 ppm arsenic, while arsenic exposure did not significantly affect the serum lipids in AB-treated mice. Liver lipid patterns were also differentially perturbed in a microbiota-dependent manner. Conclusions: Our results suggest that in mice, the gut microbiota may be a critical factor regulating arsenic-induced LXR/RXR signaling perturbation, suggesting that modulation of the gut microbiota might be an intervention strategy to reduce the toxic effects of arsenic on lipid and cholesterol homeostasis. https://doi.org/10.1289/EHP4415. Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera). Pubblicazione: Environmental health perspectives, 2019 (prima pubblicazione 2019-09-18). Identificativi: PMID 31532247 · PMCID PMC6792374 · DOI 10.1289/ehp4415. Pagina: https://europepmc.org/article/MED/31532247 — https://doi.org/10.1289/ehp4415. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito). Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0. Letto il 2026-11-10T13:47:38.726Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.